老年女性十年极低频唑来膦酸治疗:一项随机试验的开放标签扩展研究
在50例骨量减少老年女性中,33例进入5年开放标签扩展,比较0年和5.5年两次5 mg唑来膦酸(ZZ组,n=16)与基线安慰剂后5.5年单次5 mg(PZ组,n=17)对骨密度和骨转换的影响。近11年随访显示,腰椎骨密度变化两组无显著差异,全髋ZZ组优于PZ组,骨转换标志物相似。作者认为5.5年间隔给药可预防骨丢失,并认为探索极低频治疗降低骨折风险的临床试验是合理的。
要点
- 5.5年间隔5 mg唑来膦酸使ZZ组腰椎骨密度近11年保持稳定,PZ组再给药后升高。
- 11年时全髋骨密度变化ZZ组0.9% vs PZ组-2.8%(P=.006)。
- 再给药后5年内两组骨转换标志物相似。
核心结论
- 作者认为5 mg唑来膦酸以5.5年间隔给药可预防近11年的骨丢失。
- 作者认为探索极低频唑来膦酸治疗是否降低骨折风险的临床试验是合理的。
研究设计与样本
- 随机试验的开放标签扩展研究,在学术研究中心开展。
- 原始队列50例骨量减少老年女性,随机分配至单次5 mg唑来膦酸或安慰剂,平均5.5年后33例进入5年开放标签扩展。
- 所有扩展期参与者接受5 mg静脉唑来膦酸,分为0年和5.5年两次给药组(ZZ,n=16)与基线安慰剂、5.5年单次给药组(PZ,n=17)。
- 每年测量骨密度和骨转换,生成近11年数据。
主要发现
- 再给药后ZZ组骨密度保持稳定,PZ组骨密度升高。
- 11年时腰椎骨密度自基线变化ZZ组3.8%(95%CI 1.1,6.5) vs PZ组2.9%(95%CI 0.3,5.5),P=.61。
- 11年时全髋骨密度自基线变化ZZ组0.9%(95%CI -1.7,3.5) vs PZ组-2.8%(95%CI -5.3,-0.3),P=.006。
- 11年时全身骨密度自基线变化ZZ组0.4%(95%CI -0.8,1.6) vs PZ组-0.4%(95%CI -1.3,0.5),P=.14。
- 再给药后5年内PZ组与ZZ组骨转换标志物相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Intravenous zoledronate prevents bone loss and reduces fracture risk in older adults but the optimal dosing strategy required to achieve each outcome is not known. OBJECTIVE: To assess the effect of very infrequent zoledronate therapy on bone mineral density (BMD) and markers of bone turnover. DESIGN AND PARTICIPANTS: An average of 5.5 years after randomization to either a single dose of 5 mg of zoledronateor placebo, 33 of the original cohort of 50 older women with osteopenia entered a 5-year open-label extension study. SETTING: Academic research center. INTERVENTION: A 5-mg dose of intravenous zoledronate was administered to all participants. MAIN OUTCOME MEASURES: BMD and bone turnover were measured annually, generating data over almost 11 years in women who received 5 mg of zoledronate at 0 and 5.5 years (ZZ, n = 16), or placebo at baseline and 5 mg of zoledronate at 5.5 years (PZ, n = 17). RESULTS: After redosing, BMD in ZZ remained stable, while BMD in PZ increased. At 11 years, changes from baseline BMD in ZZ and PZ were 3.8% (95% confidence interval (CI) 1.1,6.5) and 2.9% (0.3,5.5) at the lumbar spine (P = .61), 0.9% (-1.7,3.5) and -2.8% (-5.3,-0.3) at the total hip (P = .006), and 0.4% (-0.8,1.6) and -0.4% (-1.3,0.5) at the total body (P = .14). Bone turnover markers were similar in the PZ and ZZ groups throughout the 5 years after redosing. CONCLUSIONS: These results suggest that zoledronate 5 mg administered at a 5.5-year interval prevents bone loss over almost 11 years. Clinical trials to investigate whether very infrequent treatment with zoledronate reduces fracture risk are justified.
引用
- Grey A, Horne A, Gamble G, et al. Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial. J Clin Endocrinol Metab. 2020. PMID: 32016386. doi:10.1210/clinem/dgaa062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。